×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Neurogene concludes merger deal with Neoleukin Therapeutics
Pharmaceutical Technology
Neurogene has concluded its merger deal with Neoleukin Therapeutics to develop genetic therapies for complex neurological ailments.
5 months ago
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
Yahoo Finance
SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical...
5 months ago
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million
Business Wire
Neurogene Inc. (NASDAQ: NGNE) (“Neurogene”), a clinical-stage company founded to bring life-changing genetic medicines to patients and...
5 months ago
Fenwick Represents Neoleukin in Merger Agreement with…
Fenwick & West LLP
Fenwick is representing Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) in its definitive merger agreement with Neurogene Inc., a clinical-stage...
10 months ago
Neoleukin, old ending: De novo protein player lays off 70% of staff, searches for strategic alternative
Fierce Biotech
The end is near for Neoleukin Therapeutics. Months after laying off 40% of its staff and dropping its lead candidate, the de novo protein...
14 months ago
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
KLAS 8 News Now
SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical...
7 months ago
Seattle-based Neoleukin folded into New York biotech after merger
The Business Journals
Donna Cochener joined Neoleukin last year as general counsel and led the company as interim CEO before the merger closed.
5 months ago
Biomed Industries, Inc. Offers to acquire Neoleukin Therapeutics, Inc. (NASDAQ:NLTX)
AccessWire
The letter described a proposal to acquire all the company's common stock for $1.60 per share which represents an 80% premium on the average...
11 months ago
Neurogene and Neoleukin Announce Definitive Merger Agreement
Yahoo Finance
Proposed merger to create Nasdaq-listed biotech company focused on advancing Neurogene's differentiated portfolio of genetic medicines for...
10 months ago
Neoleukin to merge with Neurogene for $200m in cash reserves
Pharmaceutical Technology
Neurogene and Neoleukin Therapeutics have entered a definitive agreement to merge as part of an all-stock transaction.
10 months ago